Latest News

GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates
Zika Vaccine Demonstrates 100% Protection in Preclinical Lethal Challenge ModelMalaria Vaccine Devel...
Continue Reading...
GeoVax to Present Zika Vaccine Data at the 20th Annual Conference on Vaccine Research
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, ...
Continue Reading...
GeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today ...
Continue Reading...